• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 特异性记忆 B 细胞可在中和抗体检测不到的老年人群中持续存在。

SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies.

机构信息

Division of Infection and Immunity, Institute of Immunity and Transplantation, University College London (UCL), London, United Kingdom.

Virus Reference Department, Public Health England (now called UK Health Security Agency [UKHSA]), London, United Kingdom.

出版信息

J Clin Invest. 2022 Jan 18;132(2). doi: 10.1172/JCI152042.

DOI:10.1172/JCI152042
PMID:34843448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8759779/
Abstract

Memory B cells (MBCs) can provide a recall response able to supplement waning antibodies (Abs) with an affinity-matured response better able to neutralize variant viruses. We studied a cohort of elderly care home residents and younger staff (median age of 87 years and 56 years, respectively), who had survived COVID-19 outbreaks with only mild or asymptomatic infection. The cohort was selected because of its high proportion of individuals who had lost neutralizing antibodies (nAbs), thus allowing us to specifically investigate the reserve immunity from SARS-CoV-2-specific MBCs in this setting. Class-switched spike and receptor-binding domain (RBD) tetramer-binding MBCs persisted 5 months after mild or asymptomatic SARS-CoV-2 infection, irrespective of age. The majority of spike- and RBD-specific MBCs had a classical phenotype, but we found that activated MBCs, indicating possible ongoing antigenic stimulation or inflammation, were expanded in the elderly group. Spike- and RBD-specific MBCs remained detectable in the majority of individuals who had lost nAbs, although at lower frequencies and with a reduced IgG/IgA isotype ratio. Functional spike-, S1 subunit of the spike protein- (S1-), and RBD-specific recall was also detectable by enzyme-linked immune absorbent spot (ELISPOT) assay in some individuals who had lost nAbs, but was significantly impaired in the elderly. Our findings demonstrate that a reserve of SARS-CoV-2-specific MBCs persists beyond the loss of nAbs but highlight the need for careful monitoring of functional defects in spike- and RBD-specific B cell immunity in the elderly.

摘要

记忆 B 细胞(MBC)可以提供回忆反应,能够用亲和力成熟的反应补充逐渐减弱的抗体(Abs),从而更好地中和变异病毒。我们研究了一组在 COVID-19 爆发中幸存下来的养老院居民和年轻工作人员(中位数年龄分别为 87 岁和 56 岁),他们的感染症状仅为轻度或无症状。选择该队列是因为其中有很大比例的个体失去了中和抗体(nAbs),因此我们可以在这种情况下专门研究 SARS-CoV-2 特异性 MBC 的储备免疫。无论年龄大小,在轻度或无症状 SARS-CoV-2 感染后 5 个月,发生了类别转换的刺突和受体结合域(RBD)四聚体结合 MBC 仍持续存在。大多数刺突和 RBD 特异性 MBC 具有典型表型,但我们发现活化的 MBC (表明可能存在持续的抗原刺激或炎症)在老年组中得到了扩展。在大多数失去 nAbs 的个体中仍然可以检测到刺突和 RBD 特异性 MBC,尽管频率较低,且 IgG/IgA 同型比例降低。在一些失去 nAbs 的个体中,通过酶联免疫吸附斑点(ELISPOT)测定法也可以检测到功能性刺突、刺突蛋白 S1 亚基(S1-)和 RBD 特异性回忆,但在老年人中则显著受损。我们的研究结果表明,SARS-CoV-2 特异性 MBC 的储备在失去 nAbs 后仍然存在,但突出了需要仔细监测老年人中刺突和 RBD 特异性 B 细胞免疫的功能缺陷。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/0d0a85362a69/jci-132-152042-g125.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/acb8d8710cc1/jci-132-152042-g122.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/c6addbcc612e/jci-132-152042-g123.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/f5a1493b3522/jci-132-152042-g124.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/0d0a85362a69/jci-132-152042-g125.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/acb8d8710cc1/jci-132-152042-g122.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/c6addbcc612e/jci-132-152042-g123.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/f5a1493b3522/jci-132-152042-g124.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaac/8759779/0d0a85362a69/jci-132-152042-g125.jpg

相似文献

1
SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies.SARS-CoV-2 特异性记忆 B 细胞可在中和抗体检测不到的老年人群中持续存在。
J Clin Invest. 2022 Jan 18;132(2). doi: 10.1172/JCI152042.
2
Durable SARS-CoV-2 B cell immunity after mild or severe disease.轻度或重度疾病后 SARS-CoV-2 持久的 B 细胞免疫。
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI145516.
3
Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination.新冠病毒疫苗接种后接受替代治疗的终末期慢性肾病患者中,靶向严重急性呼吸综合征冠状病毒2刺突受体结合域的特异性外周记忆B细胞的动态变化
J Med Virol. 2025 May;97(5):e70382. doi: 10.1002/jmv.70382.
4
S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.人类感染 SARS-CoV-2 后 S 蛋白反应性 IgG 和记忆 B 细胞的产生包括对 S2 亚基的广泛反应性。
mBio. 2020 Sep 25;11(5):e01991-20. doi: 10.1128/mBio.01991-20.
5
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses.SARS-CoV-2 特异性 CD4+T 细胞应答可预测感染后 1 年时广谱中和抗体和记忆 B 细胞的维持。
Cell Rep. 2022 Feb 8;38(6):110345. doi: 10.1016/j.celrep.2022.110345. Epub 2022 Jan 19.
6
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.新冠病毒感染 14 个月后 COVID-19 恢复期患者结合抗体和中和抗体的动态分析。
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
7
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.全面绘制 SARS-CoV-2 RBD 特异性中和抗体的结合热点,用于跟踪免疫逃逸变异株。
Genome Med. 2021 Oct 14;13(1):164. doi: 10.1186/s13073-021-00985-w.
8
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants.mRNA 疫苗接种可在未感染和 COVID-19 康复个体中引发强烈的记忆 B 细胞反应,使其能够识别 SARS-CoV-2 的变异株。
Immunity. 2021 Dec 14;54(12):2893-2907.e5. doi: 10.1016/j.immuni.2021.09.011. Epub 2021 Sep 21.
9
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
10
Long-term persistence of RBD memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection.SARS-CoV-2 感染中编码中和抗体的 RBD 记忆 B 细胞的长期持久性。
Cell Rep Med. 2021 Apr 20;2(4):100228. doi: 10.1016/j.xcrm.2021.100228. Epub 2021 Mar 14.

引用本文的文献

1
Dominant and cross-reactive S1-specific memory B cell response induced by primary SARS-CoV-2 infection.初次感染新型冠状病毒(SARS-CoV-2)诱导产生的显性和交叉反应性S1特异性记忆B细胞应答。
Sci Rep. 2025 Jul 1;15(1):20591. doi: 10.1038/s41598-025-06847-4.
2
Efficient boosting of Omicron-reactive memory B cells after breakthrough infection protects from repeated exposure.突破性感染后对奥密克戎反应性记忆B细胞的有效增强可预防再次感染。
iScience. 2025 Mar 25;28(4):112278. doi: 10.1016/j.isci.2025.112278. eCollection 2025 Apr 18.
3
The BNT162b2 mRNA vaccine demonstrates reduced age-associated T1 support and .

本文引用的文献

1
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans.SARS-CoV-2 感染可诱导人类骨髓浆细胞产生长期存活。
Nature. 2021 Jul;595(7867):421-425. doi: 10.1038/s41586-021-03647-4. Epub 2021 May 24.
2
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.既往感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)可在首剂疫苗接种后挽救B细胞和T细胞对变异株的反应。
Science. 2021 Apr 30;372(6549):1418-23. doi: 10.1126/science.abh1282.
3
Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses.
BNT162b2信使核糖核酸疫苗显示出与年龄相关的T1支持减少,以及……(原文此处不完整)
iScience. 2024 Sep 26;27(11):111055. doi: 10.1016/j.isci.2024.111055. eCollection 2024 Nov 15.
4
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial.鼻内候选疫苗Mambisa和肌肉注射疫苗Abdala作为新冠康复者加强剂量的安全性和免疫原性:一项1-2期随机临床试验
Vaccines (Basel). 2024 Sep 1;12(9):1001. doi: 10.3390/vaccines12091001.
5
Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.接种疫苗和未接种疫苗的老年 COVID-19 肺炎患者的免疫特征。
J Transl Med. 2024 Aug 12;22(1):755. doi: 10.1186/s12967-024-05556-2.
6
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.杨森公司的 Ad26.COV2.S 单次剂量 COVID-19 疫苗在乌干达的 12 个月队列研究中引起了强烈和持久的抗刺突 IgG 抗体反应。
Front Immunol. 2024 May 8;15:1384668. doi: 10.3389/fimmu.2024.1384668. eCollection 2024.
7
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.序贯接种新冠灭活疫苗和重组蛋白疫苗对老年人的安全性、免疫原性和保护效果:一项前瞻性纵向研究。
Signal Transduct Target Ther. 2024 May 13;9(1):129. doi: 10.1038/s41392-024-01846-9.
8
The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染与疫苗反应的免疫生物学:交叉反应性记忆反应和衰老对疗效及脱靶效应的潜在影响
Front Immunol. 2024 Feb 26;15:1345499. doi: 10.3389/fimmu.2024.1345499. eCollection 2024.
9
SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells.SARS-CoV-2 病毒在肺肺泡巨噬细胞中的持续存在受 IFN-γ 和 NK 细胞控制。
Nat Immunol. 2023 Dec;24(12):2068-2079. doi: 10.1038/s41590-023-01661-4. Epub 2023 Nov 2.
10
Can T Cells Abort SARS-CoV-2 and Other Viral Infections?T 细胞能否终止 SARS-CoV-2 及其他病毒感染?
Int J Mol Sci. 2023 Feb 22;24(5):4371. doi: 10.3390/ijms24054371.
SARS-CoV-2 及其他呼吸道病毒免疫持久性。
Trends Microbiol. 2021 Jul;29(7):648-662. doi: 10.1016/j.tim.2021.03.016. Epub 2021 Apr 8.
4
Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020.2020年英国伦敦护理院新冠病毒2型(SARS-CoV-2)感染与传播情况:报告无2019冠状病毒病病例或疫情的前瞻性观察队列研究
Lancet Reg Health Eur. 2021 Apr;3:100038. doi: 10.1016/j.lanepe.2021.100038. Epub 2021 Jan 22.
5
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.识别 SARS-CoV-2 刺突蛋白主要和次要表位的单克隆抗体的中和效力受 B.1.1.7 变异株的影响。
Immunity. 2021 Jun 8;54(6):1276-1289.e6. doi: 10.1016/j.immuni.2021.03.023. Epub 2021 Apr 1.
6
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
7
Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers.SARS-CoV-2 的血清学监测:公共卫生工作者队列的六个月趋势和抗体反应。
J Infect. 2021 May;82(5):162-169. doi: 10.1016/j.jinf.2021.03.015. Epub 2021 Mar 22.
8
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.N 端结构域抗原性分析揭示了 SARS-CoV-2 的一个弱点。
Cell. 2021 Apr 29;184(9):2332-2347.e16. doi: 10.1016/j.cell.2021.03.028. Epub 2021 Mar 16.
9
Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review.感染 SARS-CoV-2 后的抗体反应及其对免疫的影响:快速实时综述。
Ann Intern Med. 2021 Jun;174(6):811-821. doi: 10.7326/M20-7547. Epub 2021 Mar 16.
10
The effect of spike mutations on SARS-CoV-2 neutralization.刺突突变对 SARS-CoV-2 中和作用的影响。
Cell Rep. 2021 Mar 23;34(12):108890. doi: 10.1016/j.celrep.2021.108890. Epub 2021 Mar 6.